Lim P O, MacFadyen R J, Struthers A D
Cardiovascular Research Group, Department of Clinical Pharmacology and Therapeutics, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK.
Heart. 2000 Mar;83(3):257-61. doi: 10.1136/heart.83.3.257.
It remains uncertain whether angiotensin converting enzyme (ACE) inhibitors benefit all heart failure patients or just those with renin-angiotensin-aldosterone system (RAAS) activation.
To determine whether the response to an ACE inhibitor, assessed by urine sodium excretion, was different in patients with low renin versus those with high renin.
Plasma renin activity (PRA) was measured in 38 patients with stable chronic heart failure (21 male, 17 female; mean (SD) age 71 (6) years, range 59-82 years) on chronic diuretic treatment alone. They were divided into three groups: low (PRA </= 1.5 ng/ml/h, n = 11); normal (1.5 < PRA < 5, n = 14); and high (PRA > 5, n = 13). The effect of ACE inhibition was then assessed on diuretic induced natriuresis with respect to renin status.
There were no significant differences in age and sex distribution between the groups. Plasma angiotensin II and aldosterone increased serially from low to high renin groups, while 24 h urinary sodium concentrations fell from low to high renin groups (low PRA, 96.7 (39.5); normal PRA, 90.4 (26.7); high PRA, 66. 3 (18.9) mmol/l; p = 0.033), despite a higher diuretic dose in the high renin group. This blunted natriuretic effect of loop diuretics was caused by RAAS activation, which could partly be reversed by ACE inhibition. ACE inhibitors increased natriuresis by 22% in the high renin group (p = 0.029), but had no effect in the normal and low renin groups. Within the low renin group, five of the 11 patients had persistently low renin levels despite ACE inhibition. There was a non-significant reduction in natriuresis (-9.6%, p = 0.335) following ACE inhibition in this subgroup of patients.
About one third of heart failure patients in our study had low renin status and a non-activated RAAS, despite diuretic treatment. ACE inhibitors did not alter natriuresis significantly in this subgroup of patients, and enhanced natriuresis only in patients with high renin. There is thus tentative support for renin profiling in targeting ACE inhibitors to the most deserving, by showing that short term sodium retention does not occur in low renin patients if ACE inhibitors are withdrawn.
血管紧张素转换酶(ACE)抑制剂是否对所有心力衰竭患者有益,还是仅对那些肾素-血管紧张素-醛固酮系统(RAAS)激活的患者有益,目前仍不确定。
通过尿钠排泄评估,确定低肾素患者与高肾素患者对ACE抑制剂的反应是否不同。
对38例仅接受慢性利尿剂治疗的稳定型慢性心力衰竭患者(21例男性,17例女性;平均(标准差)年龄71(6)岁,范围59 - 82岁)测量血浆肾素活性(PRA)。他们被分为三组:低(PRA≤1.5 ng/ml/h,n = 11);正常(1.5 < PRA < 5,n = 14);高(PRA > 5,n = 13)。然后根据肾素状态评估ACE抑制对利尿剂诱导的利钠作用的影响。
各组之间年龄和性别分布无显著差异。血浆血管紧张素II和醛固酮从低肾素组到高肾素组依次升高,而24小时尿钠浓度从低肾素组到高肾素组下降(低PRA组,96.7(39.5);正常PRA组,90.4(26.7);高PRA组,66.3(18.9)mmol/l;p = 0.033),尽管高肾素组的利尿剂剂量更高。袢利尿剂这种减弱的利钠作用是由RAAS激活引起的,ACE抑制可部分逆转这种作用。ACE抑制剂使高肾素组的利钠作用增加22%(p = 0.029),但对正常肾素组和低肾素组无影响。在低肾素组中,11例患者中有5例尽管接受了ACE抑制,肾素水平仍持续较低。在该亚组患者中,ACE抑制后利钠作用有不显著的降低(-9.6%,p = 0.335)。
在我们的研究中,约三分之一的心力衰竭患者尽管接受了利尿剂治疗,但肾素水平较低且RAAS未激活。ACE抑制剂在该亚组患者中未显著改变利钠作用,仅在高肾素患者中增强了利钠作用。因此,通过表明停用ACE抑制剂时低肾素患者不会出现短期钠潴留,初步支持了通过肾素谱分析将ACE抑制剂靶向最适合的患者。